Skip to main content

Table 2 HIV-1 co-receptor usage and its associated influence factors

From: Co-receptor usage and prediction of v3 genotyping algorithms in hiv-1 subtype b' from paid blood donors experienced anti-retroviral therapy in chinese central province

  Treatment-naïve group N = 114 ART group N = 45  
  R5 co-receptor usage utilization X4 co-receptor usage utilization R5co-receptor usage utilization X4 co-receptor usage utilization  
CD4+T count (cells/μl)      
   CD4 < 100 8(66.7%) 4 (33.3%) 6(28.6%) 15(71.4%) p = 0.007
   100 = < CD4 < 200 13(72.2%) 5 (27.8%) 5(45.5%) 6 (54.5%)  
   CD4 > = 200 78(92.9%) 6(7.1%) 9(84.6%) 2 (15.4%)  
VL      
   VL(log10) < 4 18(90.0%) 2(10.0%) 0 11(68.7%) 7(100.0%)  
   4 = < VL(log10) = < 5 43(89.6%) 5(10.4%) 11(50.0%) 5(31.3%) p < 0.0001
   VL(log10) > 5 40(82.6%) 6(17.4%)   11(50.0%)  
Therapeutic regimen      
   AZT+DDI+NVP    9(40.9%) 13 (59.1%) p = 0.30
   D4T+DDI+NVP    13(56.5%) 10 (43.5%)  
Treatment time (months)      
   < 18    5(55.6%) 4 (44.4%) P = 0.88
   18-30    10(45.5%) 12 (54.5%)  
   >= 30    7(50.0%) 7 (50.0%)  
  1. Note: p is used to test the difference of X4 distribution between treatment-naïve and ART group.